Botensilimab and Balstilimab New Immunotherapy Strategy for MSS Colorectal Cancer скачать в хорошем качестве

Botensilimab and Balstilimab New Immunotherapy Strategy for MSS Colorectal Cancer

Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has long been considered resistant to immunotherapy — with PD-1 inhibitors alone offering little benefit. A new immunotherapy combination may be changing that paradigm. In this video, we break down botensilimab plus balstilimab (Bot/Bal), a novel dual-checkpoint strategy designed specifically for immunologically cold tumors. Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, initiates immune activation by reshaping the tumor microenvironment and depleting regulatory T cells. Balstilimab, a fully human anti-PD-1 antibody, sustains T-cell activity and prevents immune exhaustion. In a phase I study of heavily pretreated MSS metastatic colorectal cancer, this combination achieved a median overall survival of ~21 months, with durable benefit in responders — outperforming historical outcomes seen with regorafenib, trifluridine–tipiracil, fruquintinib, and even the SUNLIGHT regimen, despite limited early PFS. We also discuss: • Why OS benefit may matter more than early PFS in immune-reprogramming strategies • Safety profile and immune-related toxicity management • Availability through Expanded Access in France • What to expect from the upcoming Phase III BATTMAN trial 📖 Read the full scientific breakdown and trial analysis on OncoDaily https://oncodaily.com/oncolibrary/bot... SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/